• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Precigen (PGEN) Is Up 11.9% After PAPZIMEOS’ Launch Shifts Focus Toward Commercial Revenue Model

    Simply Wall St·03/29/2026 00:21:42
    語音播報
    • For the full year 2025, Precigen, Inc. reported revenue of US$9.68 million compared to US$3.93 million in 2024, while net loss widened to US$250.64 million and loss per share from continuing operations increased to US$1.37.
    • Despite the larger loss, Precigen’s first FDA-approved therapy PAPZIMEOS for adult recurrent respiratory papillomatosis, broad label, emerging standard-of-care status, and upcoming permanent J-code together mark a shift toward a commercial revenue model with growing reimbursement support.
    • We’ll now examine how PAPZIMEOS’s US launch and growing reimbursement support may reshape Precigen’s investment narrative and future expectations.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    Precigen Investment Narrative Recap

    For me, the core belief behind owning Precigen is that PAPZIMEOS can support a sustainable commercial business in adult recurrent respiratory papillomatosis, despite the company’s widening net losses. The latest results confirm a meaningful step up in revenue but also highlight how dependent the near term story is on continued US uptake, payer pull through, and progress toward cash flow breakeven, while the biggest risk remains that demand or pricing falls short against a growing fixed cost base.

    The most relevant development here is PAPZIMEOS’s upcoming permanent J-code, effective April 1, 2026, which should simplify billing and help reduce financial friction for providers. In the context of the recent financials, smoother reimbursement is closely tied to the key catalyst of converting broad payer coverage and emerging standard-of-care status into sustained product revenue, which is critical as Precigen works to absorb its higher operating costs.

    Yet, against this promising reimbursement progress, investors should be aware that if PAPZIMEOS uptake lags expectations, the company’s heavy spending on commercial and manufacturing infrastructure could...

    Read the full narrative on Precigen (it's free!)

    Precigen's narrative projects $299.5 million revenue and $118.4 million earnings by 2028. This requires 262.1% yearly revenue growth and about a $544 million earnings increase from $-425.9 million today.

    Uncover how Precigen's forecasts yield a $8.50 fair value, a 132% upside to its current price.

    Exploring Other Perspectives

    PGEN 1-Year Stock Price Chart
    PGEN 1-Year Stock Price Chart

    Eleven members of the Simply Wall St Community value Precigen between US$0.50 and US$41.32 per share, showing very different expectations about its potential. When you set those views against the company’s reliance on PAPZIMEOS uptake to support a costly commercial build out, it becomes clear why examining several contrasting perspectives on Precigen’s future performance can be useful.

    Explore 11 other fair value estimates on Precigen - why the stock might be a potential multi-bagger!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready For A Different Approach?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.